Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 54,759 | 188,517 | 201,643 | 226,548 | 129,793 |
| Marketable Securities | 1,547,201 | 1,595,574 | 714,967 | 692,818 | 770,579 |
| Receivables | 8,556 | 15,685 | 218,871 | 6,824 | 9,699 |
| Other current assets | 35,522 | 18,254 | 22,855 | 13,516 | 13,160 |
| TOTAL | $1,671,411 | $1,839,751 | $1,174,389 | $950,639 | $946,923 |
| Non-Current Assets | |||||
| PPE Net | 373,301 | 374,822 | 378,584 | 382,515 | 381,048 |
| Intangibles | 5,586 | 6,011 | 6,436 | 6,861 | 7,286 |
| Other Non-Current Assets | 61,715 | 47,681 | 44,772 | 45,280 | 45,355 |
| TOTAL | $440,602 | $428,514 | $429,792 | $434,656 | $433,689 |
| Total Assets | $2,112,013 | $2,268,265 | $1,604,181 | $1,385,295 | $1,380,612 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 |
| Accounts payable and accrued liabilities | 27,776 | 30,747 | 32,937 | 17,674 | 33,050 |
| Accrued Expenses | 109,629 | 96,951 | 144,351 | 117,314 | 84,116 |
| Other current liabilities | 6,023 | 11,205 | 10,675 | 10,811 | 7,375 |
| TOTAL | $283,346 | $295,220 | $347,425 | $195,487 | $194,530 |
| Non-Current Liabilities | |||||
| Long Term Debt | 824,073 | 841,579 | 163,108 | 214,883 | 200,332 |
| Deferred Revenues | 94,596 | 108,543 | 111,933 | 2,399 | 22,979 |
| Other Non-Current Liabilities | 491,446 | 488,775 | 479,695 | 431,638 | 469,355 |
| TOTAL | $1,362,626 | $1,374,129 | $694,059 | $686,392 | $666,276 |
| Total Liabilities | $1,645,972 | $1,669,349 | $1,041,484 | $881,879 | $860,806 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 141,255 | 140,857 | 140,032 | 135,810 | 138,258 |
| Common Shares | 237 | 236 | 233 | 231 | 230 |
| Retained earnings | -1,923,355 | -1,729,075 | -1,596,343 | -1,627,154 | -1,603,404 |
| Other shareholders' equity | -915 | -14,512 | 781 | 43,614 | 2,850 |
| TOTAL | $466,041 | $598,916 | $562,697 | $503,416 | $519,806 |
| Total Liabilities And Equity | $2,112,013 | $2,268,265 | $1,604,181 | $1,385,295 | $1,380,612 |